51
|
Nomellini PF, Curado MP, Oliveira MMD. Cancer Incidence in Adolescents and Young Adults in 24 Selected Populations of Latin America. J Adolesc Young Adult Oncol 2018; 7:164-173. [PMID: 29634431 DOI: 10.1089/jayao.2017.0088] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
OBJECTIVE Describe incidence rates for the most common cancers in Latin American adolescents and young adults (AYA). METHODS Incidence data were extracted from the Cancer Incidence in Five Continents series, available online (IARC). Age-standardized incidence rates and trend analysis were calculated. Trends were calculated by joinpoint regression analysis to obtain average annual percentage change values. RESULTS There were 22,990 invasive incident cancer cases in AYA between 1998 and 2007, obtained from 24 population-based cancer registries. The most common cancer in males was gonadal germ cell tumor, with incidence rates ranging from 1.7 to 7.0/100,000; in females the most common cancer was thyroid cancer, with rates ranging from 0.9 to 10.0/100,000. Incidence trends were limited to four regional populations and increased for all malignancies, in males from 1.8% to 3.4% and in females from 0.9% to 1.8%. CONCLUSIONS Cancer incidence rates in Latin American AYA are low. There are few PBCRs with long-term data, and therefore, the results herein presented are a partial view of cancer in Latin American AYA populations.
Collapse
Affiliation(s)
- Patrícia Ferreira Nomellini
- 1 Postgraduate Program in Health Sciences, Federal University of Goiás , Goiânia, Brazil .,2 Health Secretariat of the state of Tocantins , Palmas, Brazil .,3 Health Secretariat of the city of Palmas , Palmas, Brazil
| | - Maria Paula Curado
- 1 Postgraduate Program in Health Sciences, Federal University of Goiás , Goiânia, Brazil .,4 Epidemiology and Statistics Group, ACCamargo Cancer Center , São Paulo, Brazil .,5 International Prevention Research Institute , Lyon, France
| | - Max Moura de Oliveira
- 4 Epidemiology and Statistics Group, ACCamargo Cancer Center , São Paulo, Brazil .,6 Graduate Program in Public Health, School of Public Health, University of São Paulo , São Paulo, Brazil
| |
Collapse
|
52
|
Scafidi J, Ritter J, Talbot BM, Edwards J, Chew LJ, Gallo V. Age-Dependent Cellular and Behavioral Deficits Induced by Molecularly Targeted Drugs Are Reversible. Cancer Res 2018; 78:2081-2095. [PMID: 29559476 DOI: 10.1158/0008-5472.can-17-2254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 01/12/2018] [Accepted: 02/09/2018] [Indexed: 11/16/2022]
Abstract
Newly developed targeted anticancer drugs inhibit signaling pathways commonly altered in adult and pediatric cancers. However, as these pathways are also essential for normal brain development, concerns have emerged of neurologic sequelae resulting specifically from their application in pediatric cancers. The neural substrates and age dependency of these drug-induced effects in vivo are unknown, and their long-term behavioral consequences have not been characterized. This study defines the age-dependent cellular and behavioral effects of these drugs on normally developing brains and determines their reversibility with post-drug intervention. Mice at different postnatal ages received short courses of molecularly targeted drugs in regimens analagous to clinical treatment. Analysis of rapidly developing brain structures important for sensorimotor and cognitive function showed that, while adult administration was without effect, earlier neonatal administration of targeted therapies attenuated white matter oligodendroglia and hippocampal neuronal development more profoundly than later administration, leading to long-lasting behavioral deficits. This functional impairment was reversed by rehabilitation with physical and cognitive enrichment. Our findings demonstrate age-dependent, reversible effects of these drugs on brain development, which are important considerations as treatment options expand for pediatric cancers.Significance: Targeted therapeutics elicit age-dependent long-term consequences on the developing brain that can be ameliorated with environmental enrichment. Cancer Res; 78(8); 2081-95. ©2018 AACR.
Collapse
Affiliation(s)
- Joseph Scafidi
- Neurology, Children's National Health System, Washington, D.C. .,Center for Neuroscience Research, Children's Research Institute, Children's National Health System, Washington, D.C
| | - Jonathan Ritter
- Center for Neuroscience Research, Children's Research Institute, Children's National Health System, Washington, D.C
| | - Brooke M Talbot
- Center for Neuroscience Research, Children's Research Institute, Children's National Health System, Washington, D.C
| | - Jorge Edwards
- Center for Neuroscience Research, Children's Research Institute, Children's National Health System, Washington, D.C
| | - Li-Jin Chew
- Center for Neuroscience Research, Children's Research Institute, Children's National Health System, Washington, D.C
| | - Vittorio Gallo
- Center for Neuroscience Research, Children's Research Institute, Children's National Health System, Washington, D.C
| |
Collapse
|
53
|
Zhang AS, Ostrom QT, Kruchko C, Rogers L, Peereboom DM, Barnholtz-Sloan JS. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol 2018; 19:726-735. [PMID: 28039365 DOI: 10.1093/neuonc/now252] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Complete prevalence proportions illustrate the burden of disease in a population. This study estimates the 2010 complete prevalence of malignant primary brain tumors overall and by Central Brain Tumor Registry of the United States (CBTRUS) histology groups, and compares the brain tumor prevalence estimates to the complete prevalence of other common cancers as determined by the Surveillance, Epidemiology, and End Results Program (SEER) by age at prevalence (2010): children (0-14 y), adolescent and young adult (AYA) (15-39 y), and adult (40+ y). Methods Complete prevalence proportions were estimated using a novel regression method extended from the Completeness Index Method, which combines survival and incidence data from multiple sources. In this study, two datasets, CBTRUS and SEER, were used to calculate complete prevalence estimates of interest. Results Complete prevalence for malignant primary brain tumors was 47.59/100000 population (22.31, 48.49, and 57.75/100000 for child, AYA, and adult populations). The most prevalent cancers by age were childhood leukemia (36.65/100000), AYA melanoma of the skin (66.21/100000), and adult female breast (1949.00/100000). The most prevalent CBTRUS histologies in children and AYA were pilocytic astrocytoma (6.82/100000, 5.92/100000), and glioblastoma (12.76/100000) in adults. Conclusions The relative impact of malignant primary brain tumors is higher among children than any other age group; it emerges as the second most prevalent cancer among children. Complete prevalence estimates for primary malignant brain tumors fills a gap in overall cancer knowledge, which provides critical information toward public health and health care planning, including treatment, decision making, funding, and advocacy programs.
Collapse
Affiliation(s)
- Adah S Zhang
- Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.,Department of Statistical Sciences, Sandia National Laboratories, Albuquerque, New Mexico, USA
| | - Quinn T Ostrom
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.,Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA
| | - Carol Kruchko
- Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA
| | - Lisa Rogers
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.,Brain Tumor and Neuro-Oncology Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA
| | - David M Peereboom
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.,Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Jill S Barnholtz-Sloan
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.,Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA
| |
Collapse
|
54
|
Du SX, Jia YR, Ren SQ, Gong XJ, Tang H, Wan-Shui W, Li-Ming S. The protective effects of Bacillus licheniformis preparation on gastrointestinal disorders and inflammation induced by radiotherapy in pediatric patients with central nervous system tumor. Adv Med Sci 2018; 63:134-139. [PMID: 29120854 DOI: 10.1016/j.advms.2017.09.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Revised: 08/01/2017] [Accepted: 09/26/2017] [Indexed: 12/20/2022]
Abstract
PURPOSE we studied the effect of Bacillus licheniformis preparation (ZCS) on CNST (central nervous system tumor) patients undergoing the gastrointestinal symptoms and inflammation induced by radiotherapy. MATERIALS AND METHODS 160 CNST patients with craniospinal irradiation (CSI) treatment were divided into experiment and control group. The experiment group patients took one capsule per time of ZCS and three times a day until the end of radiotherapy, starting one day before radiotherapy. While the patients in control group were administrated placebo without any probiotics. Serum from one day before radiotherapy and the first day after radiotherapy were collected to measure the ET, CRP, TNF-α, IL-1β and IL-6. RESULTS More than 70% CNST pediatric patients suffered from different degrees of gastrointestinal symptoms after radiotherapy, including mouth ulcer, nausea, vomiting, abdominal pain and diarrhea. And there was an obviously increased of serum ET, TNF-α, IL-1β, IL-6 and CRP after RT. Importantly, a markedly decreased of ET, CRP and inflammatory cytokines were detected in the experiment group comparing to the control group after radiotherapy, as well as the relief of the gastrointestinal symptoms. However, improvement of probiotics (or ZCS) of the survival rate of CNST children and the recurrence of tumor are not observed in this study. CONCLUSIONS Prophylactically administrated ZCS during radiotherapy for CNST patients can relieve RT-related gastrointestinal symptoms and inflammatory reaction.
Collapse
Affiliation(s)
- Shu-Xu Du
- Department of Pediatrics, BeijingShijitan Hospital, Capital Medical University, Beijing, 100038, China.
| | - Yong-Rui Jia
- Health Science Center, Peking University, Beijing, 100191, China
| | - Si-Qi Ren
- Department of Pediatrics, BeijingShijitan Hospital, Capital Medical University, Beijing, 100038, China
| | - Xiao-Jun Gong
- Department of Pediatrics, BeijingShijitan Hospital, Capital Medical University, Beijing, 100038, China
| | - Hong Tang
- Department of Pediatrics, BeijingShijitan Hospital, Capital Medical University, Beijing, 100038, China
| | - Wu Wan-Shui
- Department of Pediatrics, BeijingShijitan Hospital, Capital Medical University, Beijing, 100038, China
| | - Sun Li-Ming
- Department of Pediatrics, BeijingShijitan Hospital, Capital Medical University, Beijing, 100038, China
| |
Collapse
|
55
|
Bello Roufai D, Caillet P, Lapôtre-Ledoux B, Trecherel E, Bauchet L, Chauffert B, Ganry O. Incidence and survival rates for adult malignant neuro-epithelial brain tumors in the Somme county (France): A retrospective, population-based study from 2003 to 2013. J Cancer Policy 2018. [DOI: 10.1016/j.jcpo.2017.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
56
|
Mwita CC, Rowland T, Gwer S. Burden of brain tumors in low- and middle-income countries: a systematic review protocol. JBI DATABASE OF SYSTEMATIC REVIEWS AND IMPLEMENTATION REPORTS 2018; 16:609-614. [PMID: 29521859 DOI: 10.11124/jbisrir-2017-003424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
REVIEW QUESTION/OBJECTIVE The objective of this review is to determine the best available evidence on the burden of brain tumors in low- and middle-income countries (LAMICs). More specifically, the objective is to determine the incidence and prevalence rates for brain tumors in LAMICs.
Collapse
Affiliation(s)
- Clifford C Mwita
- School of Medicine, Moi University, Eldoret, Kenya
- Afya Research Africa (ARA): a Joanna Briggs Institute Centre of Excellence
| | - Thabo Rowland
- School of Medicine, University of Nairobi, Nairobi, Kenya
| | - Samson Gwer
- School of Medicine, Kenyatta University, Nairobi, Kenya
- Afya Research Africa (ARA): a Joanna Briggs Institute Centre of Excellence
| |
Collapse
|
57
|
Treatment of a glioblastoma multiforme dural metastasis with stereotactic radiosurgery: A case report and select review of the literature. J Clin Neurosci 2018; 48:118-121. [DOI: 10.1016/j.jocn.2017.11.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 11/15/2017] [Indexed: 11/23/2022]
|
58
|
Abstract
Central nervous tumors are the leading cause of death from cancer in the pediatric population. Advances in care for pediatric neuro-oncology patients have led to improved survival rates. As survivorship increases, care of the sequelae of the tumor and its treatment become more important for long-term quality of life. A significant portion of the brain is involved in vision. Pediatric brain tumors can distort, damage, and destroy portions of the brain involved in both the afferent and efferent vision pathways. This interruption of normal visual pathways can lead to permanent vision loss or other morbidities such as strabismus and nystagmus. This article reviews the presenting symptoms and signs of brain tumors in children and adolescents, as well as the effects of the tumor and its treatment on the afferent and efferent visual pathways. Strategies for monitoring during treatment, and management of sequelae are reviewed. Through systematic evaluation and monitoring of pediatric neuro-oncology patients, those at risk for vision loss or tumor progression can be identified.
Collapse
|
59
|
Acheampong DO, Adokoh CK, Asante DB, Asiamah EA, Barnie PA, Bonsu DOM, Kyei F. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomed Pharmacother 2017; 97:225-232. [PMID: 29091870 DOI: 10.1016/j.biopha.2017.10.100] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/11/2017] [Accepted: 10/21/2017] [Indexed: 12/20/2022] Open
Abstract
The standard therapy of AML for many years has been chemotherapy with or without stem transplantation. However, there has not been any tangible improvement in this treatment beyond induction through chemotherapy and consolidation with allogeneic stem cell transplantation or chemotherapy. Residual AML cells which later cause relapse mostly persist even after rigorous standard therapy. It is imperative therefore to find an alternative therapy that can take care of the residual AML cells. With a better understanding of how the immune system works to destroy tumor cells and inhibit their growth, another therapeutic option immunotherapy has emerged to address the difficulties associated with the standard therapy. Identification of leukemia-associated antigens (LAA) and the fact that T and NK cells can be activated to exert cytotoxicity on AML cells have further introduced diverse immunotherapeutic development strategies. This review discusses the merits of current immunotherapeutic strategies such as the use of antibodies, adoptive T cells and alloreactive NK cell, and vaccination as against the standard therapy of AML.
Collapse
Affiliation(s)
| | - Christian K Adokoh
- Department of Forensic Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Du-Bois Asante
- Department of Forensic Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Ernest A Asiamah
- Department of Biomedical Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Prince A Barnie
- Department of Forensic Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Dan O M Bonsu
- Department of Forensic Sciences, University of Cape Coast, Cape Coast, Ghana
| | - Foster Kyei
- Department of Molecular Biology and Biotechnology, University of Cape Coast, Ghana
| |
Collapse
|
60
|
Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz Ł, Sekerija M, Žagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Sfakianos G, Nikas I, Kosmidis S, Razis E, Pourtsidis A, Kantzanou M, Dessypris N, Petridou ET. Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. Eur J Cancer 2017; 86:46-58. [DOI: 10.1016/j.ejca.2017.08.030] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 08/23/2017] [Accepted: 08/25/2017] [Indexed: 11/30/2022]
|
61
|
Tran LT, Lai HTM, Koriyama C, Uwatoko F, Akiba S. The association between high birth weight and the risks of childhood CNS tumors and leukemia: an analysis of a US case-control study in an epidemiological database. BMC Cancer 2017; 17:687. [PMID: 29037176 PMCID: PMC5644053 DOI: 10.1186/s12885-017-3681-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 10/09/2017] [Indexed: 11/25/2022] Open
Abstract
Background High birth weight (BW), 4000 g or larger, is an established risk factor for childhood leukemia. However, its association with central nervous system (CNS) tumor risk is yet unclear. The present study examined it, analyzing data obtained from a case-control study conducted among three states from the US. The association with childhood leukemia risk was also further examined. Methods In this study, a data set provided by the Comprehensive Epidemiologic Data Resource was analyzed with an official permission. The original case-control study was conducted to examine the association between paternal preconception exposure to ionizing radiation and childhood cancer risk. Cases with childhood cancer were mainly ascertained from local hospitals, and controls were selected, matched with birth year (1-year category), county of residence, sex, ethnicity and maternal age (+/−2 years). Since the ID numbers were unavailable, conventional logistic analyses were conducted adjusting for those matching variables except for the county of residence. In addition to those variables, gestational age, age at diagnosis and study sites as covariables were included in the logistic models. Results Analyzed subjects were 72 CNS tumor cases, 124 leukemia cases and 822 controls born from 1945 to 1989. The odds ratios (ORs) of CNS tumor risk for children with low BWs (<2500 g) and high BWs (>4000 g) were 2.0 (95% confidence interval [CI]) = 0.7, 5.9) and 2.5 (95%CI = 1.2, 5.2)], respectively. When high-BW children were restricted to those who were large for gestational age (LGA), the OR for high-BW children remained similar (OR = 2.7; 95%CI = 1.1, 6.2). On the other hand, the ORs of leukemia risk for children with low and high BWs were 0.8 (95%CI = 0.2, 3.0) and 1.4 (95%CI = 0.7, 2.6), respectively. In the normal range of BW (2500–4000 g), higher BW was positively associated with CNS tumor risk (beta = 0.0011, p for trend = 0.012). However, the association with leukemia risk was not significant (beta = −0.0002, p for trend = 0.475). Conclusion High-BW and LGA children had an elevated childhood CNS tumor risk. In the normal BW range, the BW itself was positively related to CNS tumor risk. No significant association between BW and childhood leukemia risk was observed in this study. Electronic supplementary material The online version of this article (10.1186/s12885-017-3681-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Long Thanh Tran
- Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8544, Japan
| | - Hang Thi Minh Lai
- Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8544, Japan
| | - Chihaya Koriyama
- Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8544, Japan
| | - Futoshi Uwatoko
- Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8544, Japan
| | - Suminori Akiba
- Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8544, Japan.
| |
Collapse
|
62
|
Tibæk M, Forchhammer HB, Dehlendorff C, Johnsen SP, Kammersgaard LP. Incidence and mortality of acquired brain injury in young Danish adults between 1994 and 2013: a nationwide study. Brain Inj 2017; 31:1455-1462. [PMID: 28956631 DOI: 10.1080/02699052.2017.1376757] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND We estimated the annually incidence and mortality of acquired brain injury (ABI) in people aged 15-30 years during 1994-2013. METHODS All Danes with a first-ever hospital diagnosis of ABI, including traumatic brain injury (TBI), encephalopathy, CNS-infection or brain tumour, were identified in the Danish National Patient Register. Incidence rates (IRs) and estimated annual percentage changes (EAPC) were estimated by Poisson regression. Mortality was estimated by the Kaplan-Meier estimator and adjusted hazard ratios (aHR) were computed using Cox regression with 1994-1998. RESULTS A total of 10,542 individuals were hospitalized with a first-time diagnosis of ABI. The IR for ABI decreased from 63.36 to 33.91/100,000 person-years from 1994 to 2013 [EAPC: -2.78% (95% CI: -3.26 to -2.28)] mainly driven by a decreasing IR of TBI [EAPC: -6.53% (95% CI: -9.57 to -3.39)] during 2007-2013. IRs of brain tumour and CNS infections also decreased significantly. The mortality after ABI tended to be higher during 1999-2013 compared to 1994-1998. For brain tumour, the 1-year mortality decreased significantly [2009-2013 aHR: 0.41 (95% CI: 0.23-0.72)]. CONCLUSION Incidence of hospitalisations for ABI and in particular TBI has decreased significantly. Overall, the mortality after ABI has not improved, but the mortality after brain tumour has decreased significantly.
Collapse
Affiliation(s)
- Maiken Tibæk
- a National study of young survivors of brain Injury, Department of Neurology, Rigshospitalet , University of Copenhagen , Copenhagen , Denmark
| | - Hysse Birgitte Forchhammer
- a National study of young survivors of brain Injury, Department of Neurology, Rigshospitalet , University of Copenhagen , Copenhagen , Denmark
| | - Christian Dehlendorff
- b Statistics, Statistics and Pharmacoepidemiology , Danish Cancer Society Research Center , Copenhagen , Denmark
| | - Søren Paaske Johnsen
- c Department of Clinical Epidemiology , Aarhus University Hospital , Aarhus , Denmark
| | - Lars Peter Kammersgaard
- d Research Unit on Brain Injury Rehabilitation Copenhagen (RUBRIC), Department of Neurorehabilitation, TBI Unit, Rigshospitalet , University of Copenhagen , Copenhagen,Denmark
| |
Collapse
|
63
|
Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM, Guldberg R, Gradel KO. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol 2017; 135:571-579. [PMID: 28861666 DOI: 10.1007/s11060-017-2607-5] [Citation(s) in RCA: 164] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Accepted: 08/20/2017] [Indexed: 01/18/2023]
Abstract
In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for <3 months duration, and headache <1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I-IV showed decreasing survival with increasing grade. Glioma grade I-IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.
Collapse
Affiliation(s)
- Birthe Krogh Rasmussen
- Department of Neurology, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark
| | - Steinbjørn Hansen
- Department of Oncology, Odense University Hospital, 5000, Odense C, Denmark. .,Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark.
| | - René J Laursen
- Department of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark
| | | | - Henrik Schultz
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - Bente Mertz Nørgård
- Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark.,Center for Clinical Epidemiology, Odense University Hospital, Odense C, Denmark
| | - Rikke Guldberg
- Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark.,Center for Clinical Epidemiology, Odense University Hospital, Odense C, Denmark
| | - Kim Oren Gradel
- Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark.,Center for Clinical Epidemiology, Odense University Hospital, Odense C, Denmark
| |
Collapse
|
64
|
Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. J Neurooncol 2017; 135:433-441. [DOI: 10.1007/s11060-017-2594-6] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 08/13/2017] [Indexed: 10/19/2022]
|
65
|
Gittleman H, Cote DJ, Ostrom QT, Kruchko C, Smith TR, Claus EB, Barnholtz-Sloan JS. Do race and age vary in non-malignant central nervous system tumor incidences in the United States? J Neurooncol 2017; 134:269-277. [PMID: 28667594 DOI: 10.1007/s11060-017-2543-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 06/26/2017] [Indexed: 12/11/2022]
Abstract
Epidemiological analyses of many cancers have demonstrated differences in incidence and outcome for patients from different racial backgrounds. The aim of this study was to determine the incidence of non-malignant CNS tumors by race and age to identify incidence variance. Data from the Central Brain Tumor Registry of the United States (CBTRUS) from 2009 to 2013 were used to calculate age-adjusted incidence rates (IR) per 100,000 population and 95% confidence intervals for selected tumors overall, by race, age group, and race stratified by age group. In those aged 0-14 years, Whites had significantly greater IR of neuronal and mixed neuronal-glial tumors (IR = 0.37) compared to Others (IR = 0.26) and Blacks (IR = 0.24). In those 15-39 years, Blacks had significantly greater IR of tumors of the pituitary (IR = 3.80) than Others (IR = 3.29) and Whites (IR = 3.15), and significantly greater IR of grade I meningioma (IR = 1.93) than Whites (IR = 1.59) and Others (IR = 1.21). In those 40 years and older, Blacks had significantly greater IR of grade I meningioma (IR = 19.16) compared to Whites (IR = 15.77) and Others (IR = 15.32), and significantly greater IR of tumors of the pituitary (IR = 10.47) than Others (IR = 5.85) and Whites (IR = 4.99). Others had significantly greater IR of nerve sheath tumors (IR = 4.00) compared to Whites (IR = 3.46) and Blacks (IR = 1.64). The incidence of non-malignant CNS tumors differs significantly by race and age in the USA. These differences may contribute to previously-described health outcome disparities.
Collapse
Affiliation(s)
- Haley Gittleman
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Central Brain Tumor Registry of the United States, Hinsdale, IL, USA
| | - David J Cote
- Cushing Neurosurgical Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA
| | - Quinn T Ostrom
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Central Brain Tumor Registry of the United States, Hinsdale, IL, USA
| | - Carol Kruchko
- Central Brain Tumor Registry of the United States, Hinsdale, IL, USA
| | - Timothy R Smith
- Cushing Neurosurgical Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA
| | - Elizabeth B Claus
- Cushing Neurosurgical Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA
| | - Jill S Barnholtz-Sloan
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. .,Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.
| |
Collapse
|
66
|
Abstract
Brain tumors are the commonest solid tumor in children, leading to significant cancer-related mortality. Several hereditary syndromes associated with brain tumors are nonfamilial. Ionizing radiation is a well-recognized risk factor for brain tumors. Several industrial exposures have been evaluated for a causal association with brain tumor formation but the results are inconclusive. A casual association between the common mutagens of tobacco, alcohol, or dietary factors has not yet been established. There is no clear evidence that the incidence of brain tumors has changed over time. This article presents the descriptive epidemiology of the commonest brain tumors of children and adults.
Collapse
Affiliation(s)
- Katharine A McNeill
- Division of Neuroepidemiology, Department of Neurology, New York University School of Medicine, and the Laura and Isaac Perlmutter Cancer Center, 240 East 38th Street, 19th Floor, New York, NY 10016, USA.
| |
Collapse
|
67
|
Is mortality due to primary malignant brain and other central nervous system tumors decreasing? J Neurooncol 2017; 133:265-275. [PMID: 28470430 DOI: 10.1007/s11060-017-2449-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 04/11/2017] [Indexed: 10/19/2022]
Abstract
Primary malignant brain and other central nervous system tumors (BT) are a rare cancer that causes morbidity and mortality disproportionate to their incidence. This study presents the most up-to-date mortality data for malignant BT in the United States (US) by histology groupings, age, race, and sex. Mortality rates for malignant BT were generated using the Center for Disease Control's National Vital Statistics Systems (NVSS, ~100% of US) data from 1975 to 2012. Histology-specific incidence-based mortality rates were calculated using the National Cancer Institute's Surveillance, Epidemiology, and End-Results 9 (SEER9, ~9.4% of US) data from 1975 to 2012. Joinpoint modeling was used to estimate trends. Mortality was similar in both the NVSS and SEER9 datasets. Overall, mortality from 1975 to 2012 was higher among men, higher in older individuals, and higher in Whites compared to other races. Persons age 65+ years had significant increases in mortality for all malignant tumors overall and for glioma histologies, while persons age <20 years had no significant changes in mortality. This study reports up-to-date mortality rates by histology groupings, age, race, and sex for malignant BT. There have been no significant changes in overall mortality due to these tumors from 1975 to 2012. There have been significant increases in mortality in the elderly (age 65+ years), especially those age 75-84 years, mirroring the effect of overall population aging. Examining age-, race-, sex-, and histology-specific morality at the population level can provide important information for clinicians, researchers, and public health planning.
Collapse
|
68
|
Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. J Neurooncol 2017; 133:17-25. [PMID: 28397028 DOI: 10.1007/s11060-017-2414-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 04/03/2017] [Indexed: 12/27/2022]
Abstract
Measuring tumor-specific trends in incidence is necessary to elucidate tumor-type contribution to overall cancer burden in the US population. Recently, there have been conflicting reports concerning the incidence of oligodendrogliomas (OD) and anaplastic oligodendrogliomas (AOD). Therefore, our goal was to examine trends in OD and AOD incidence and survival by age, gender and race. Data was analyzed from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2013. Age-adjusted incidence rates per 100,000 person-years with 95% confidence intervals (CI) and annual percent changes (APCs) with 95% CI were calculated for OD and AOD by age, sex and race. Survival rates were calculated for age, sex and race using a subset of the CBTRUS data. OD and AOD incidence peaked at 36-40 and 56-60 years, respectively. AOD:OD ratio increased up to age 75. Overall, OD and AOD incidence decreased [OD: APC -3.2 (2000-2013), AOD: -6.5 (2000-2007)]. OD incidence was highest in Whites but decreased significantly (2000-2013: APC -3.1) while incidence in Black populations did not significantly decrease (2000-2013: APC -1.6). Survival rates decreased with advancing age for OD, while persons aged 0-24 had the lowest survival for AOD. The current study reports a decrease in overall OD and AOD incidence from 2000 to 2013. Furthermore, AOD makes up an increasing proportion of oligodendroglial tumors up to age 75. Lower AOD survival in 0-24 years old may indicate molecular differences in pediatric cases. Thus, surveillance of tumor-specific trends by age, race and sex can reveal clinically relevant variations.
Collapse
|
69
|
Nilsson J, Holgersson G, Carlsson T, Henriksson R, Bergström S, Bergqvist M. Incidence trends in high-grade primary brain tumors in males and females. Oncol Lett 2017; 13:2831-2837. [PMID: 28454474 DOI: 10.3892/ol.2017.5770] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Accepted: 12/06/2016] [Indexed: 12/24/2022] Open
Abstract
The focus of the present review is to investigate whether there is a variation in the incidence rates between male and female patients with high-grade primary brain tumors and if there are altered incidence rates associated with the time at which they were diagnosed. Previous studies identified in internationally peer-reviewed journals were identified using a systematic search of the PubMed database. Due to the difficulties in data interpretation, studies that exclusively included patient data classified prior to the 2nd edition of the World Health Organization histological classification system of brain tumors were excluded. The overall incidence rates and incidence trends of male and female patients were analyzed separately. The mean age-adjusted overall incidence rate in the male population was 1.27 per 100,000 compared with 0.89 per 100,000 in the female population. The variance between the two genders differed and a Wilcoxon rank-sum test indicated that there was no significant difference in the incidence rate of high-grade primary brain tumors between males and females (P=0.3658). Furthermore, there was no significant difference in incidence rate trend between 1996-2004 and 2005-2010 for male or female populations (P=0.101 and P=0.472, respectively). The results from the present systematic review did not demonstrate a significant difference in incidence rate between the two genders. Therefore, the results from the current study are considered to be preliminary and further studies are required to elucidate this issue.
Collapse
Affiliation(s)
- Jonas Nilsson
- Centre for Research and Development, Uppsala University/Region Gävleborg, SE-801 87 Gävle, Sweden.,Department of Radiation Sciences and Oncology, Umeå University Hospital, SE-901 87 Umeå, Sweden.,Department of Radiology, Gävle Hospital, SE-801 88 Gävle, Sweden
| | - Georg Holgersson
- Centre for Research and Development, Uppsala University/Region Gävleborg, SE-801 87 Gävle, Sweden.,Department of Oncology, Gävle Hospital, SE-801 88 Gävle, Sweden
| | - Tobias Carlsson
- Department of Oncology, Gävle Hospital, SE-801 88 Gävle, Sweden
| | - Roger Henriksson
- Department of Radiation Sciences and Oncology, Umeå University Hospital, SE-901 87 Umeå, Sweden.,Regional Cancer Center Stockholm-Gotland, Västgötagatan 2, SE-102 39 Stockholm, Sweden
| | - Stefan Bergström
- Centre for Research and Development, Uppsala University/Region Gävleborg, SE-801 87 Gävle, Sweden.,Department of Oncology, Gävle Hospital, SE-801 88 Gävle, Sweden
| | - Michael Bergqvist
- Centre for Research and Development, Uppsala University/Region Gävleborg, SE-801 87 Gävle, Sweden.,Department of Radiation Sciences and Oncology, Umeå University Hospital, SE-901 87 Umeå, Sweden.,Department of Oncology, Gävle Hospital, SE-801 88 Gävle, Sweden
| |
Collapse
|
70
|
McKenzie LM, Allshouse WB, Byers TE, Bedrick EJ, Serdar B, Adgate JL. Childhood hematologic cancer and residential proximity to oil and gas development. PLoS One 2017; 12:e0170423. [PMID: 28199334 PMCID: PMC5310851 DOI: 10.1371/journal.pone.0170423] [Citation(s) in RCA: 69] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Accepted: 01/04/2017] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Oil and gas development emits known hematological carcinogens, such as benzene, and increasingly occurs in residential areas. We explored whether residential proximity to oil and gas development was associated with risk for hematologic cancers using a registry-based case-control study design. METHODS Participants were 0-24 years old, living in rural Colorado, and diagnosed with cancer between 2001-2013. For each child in our study, we calculated inverse distance weighted (IDW) oil and gas well counts within a 16.1-kilometer radius of residence at cancer diagnosis for each year in a 10 year latency period to estimate density of oil and gas development. Logistic regression, adjusted for age, race, gender, income, and elevation was used to estimate associations across IDW well count tertiles for 87 acute lymphocytic leukemia (ALL) cases and 50 non-Hodgkin lymphoma (NHL) cases, compared to 528 controls with non-hematologic cancers. FINDINGS Overall, ALL cases 0-24 years old were more likely to live in the highest IDW well count tertiles compared to controls, but findings differed substantially by age. For ages 5-24, ALL cases were 4.3 times as likely to live in the highest tertile, compared to controls (95% CI: 1.1 to 16), with a monotonic increase in risk across tertiles (trend p-value = 0.035). Further adjustment for year of diagnosis increased the association. No association was found between ALL for children aged 0-4 years or NHL and IDW well counts. While our study benefited from the ability to select cases and controls from the same population, use of cancer-controls, the limited number of ALL and NHL cases, and aggregation of ages into five year ranges, may have biased our associations toward the null. In addition, absence of information on O&G well activities, meteorology, and topography likely reduced temporal and spatial specificity in IDW well counts. CONCLUSION Because oil and gas development has potential to expose a large population to known hematologic carcinogens, further study is clearly needed to substantiate both our positive and negative findings. Future studies should incorporate information on oil and gas development activities and production levels, as well as levels of specific pollutants of interest (e.g. benzene) near homes, schools, and day care centers; provide age-specific residential histories; compare cases to controls without cancer; and address other potential confounders, and environmental stressors.
Collapse
Affiliation(s)
- Lisa M. McKenzie
- Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz Campus, Aurora, Colorado, United States of America
| | - William B. Allshouse
- Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz Campus, Aurora, Colorado, United States of America
| | - Tim E. Byers
- Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Campus, Aurora, Colorado, United States of America
| | - Edward J. Bedrick
- Epidemiology and Biostatistics Department, Mel &Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, United States of America
| | - Berrin Serdar
- Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz Campus, Aurora, Colorado, United States of America
| | - John L. Adgate
- Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz Campus, Aurora, Colorado, United States of America
| |
Collapse
|
71
|
Elliott EG, Trinh P, Ma X, Leaderer BP, Ward MH, Deziel NC. Unconventional oil and gas development and risk of childhood leukemia: Assessing the evidence. THE SCIENCE OF THE TOTAL ENVIRONMENT 2017; 576:138-147. [PMID: 27783932 PMCID: PMC6457992 DOI: 10.1016/j.scitotenv.2016.10.072] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 10/09/2016] [Accepted: 10/10/2016] [Indexed: 05/17/2023]
Abstract
The widespread distribution of unconventional oil and gas (UO&G) wells and other facilities in the United States potentially exposes millions of people to air and water pollutants, including known or suspected carcinogens. Childhood leukemia is a particular concern because of the disease severity, vulnerable population, and short disease latency. A comprehensive review of carcinogens and leukemogens associated with UO&G development is not available and could inform future exposure monitoring studies and human health assessments. The objective of this analysis was to assess the evidence of carcinogenicity of water contaminants and air pollutants related to UO&G development. We obtained a list of 1177 chemicals in hydraulic fracturing fluids and wastewater from the U.S. Environmental Protection Agency and constructed a list of 143 UO&G-related air pollutants through a review of scientific papers published through 2015 using PubMed and ProQuest databases. We assessed carcinogenicity and evidence of increased risk for leukemia/lymphoma of these chemicals using International Agency for Research on Cancer (IARC) monographs. The majority of compounds (>80%) were not evaluated by IARC and therefore could not be reviewed. Of the 111 potential water contaminants and 29 potential air pollutants evaluated by IARC (119 unique compounds), 49 water and 20 air pollutants were known, probable, or possible human carcinogens (55 unique compounds). A total of 17 water and 11 air pollutants (20 unique compounds) had evidence of increased risk for leukemia/lymphoma, including benzene, 1,3-butadiene, cadmium, diesel exhaust, and several polycyclic aromatic hydrocarbons. Though information on the carcinogenicity of compounds associated with UO&G development was limited, our assessment identified 20 known or suspected carcinogens that could be measured in future studies to advance exposure and risk assessments of cancer-causing agents. Our findings support the need for investigation into the relationship between UO&G development and risk of cancer in general and childhood leukemia in particular.
Collapse
Affiliation(s)
- Elise G Elliott
- Yale School of Public Health, Yale University, 60 College St., New Haven, CT 06520, USA
| | - Pauline Trinh
- Yale School of Public Health, Yale University, 60 College St., New Haven, CT 06520, USA
| | - Xiaomei Ma
- Yale School of Public Health, Yale University, 60 College St., New Haven, CT 06520, USA
| | - Brian P Leaderer
- Yale School of Public Health, Yale University, 60 College St., New Haven, CT 06520, USA
| | - Mary H Ward
- National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Bethesda, MD 20850, USA
| | - Nicole C Deziel
- Yale School of Public Health, Yale University, 60 College St., New Haven, CT 06520, USA..
| |
Collapse
|
72
|
La neuro-oncologie des adolescents et adultes jeunes (AJAS) : place d’une RCP nationale. Au nom de l’ANOCEF, GO-AJA et de la SFCE. Bull Cancer 2016; 103:1050-1056. [DOI: 10.1016/j.bulcan.2016.10.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 10/08/2016] [Accepted: 10/09/2016] [Indexed: 12/28/2022]
|
73
|
Nilsson J, Holgersson G, Carlsson T, Henriksson R, Bergstrom S, Bergqvist M. Incidence Rates in Low-Grade Primary Brain Tumors: Are There Differences Between Men and Women? A Systematic Review. World J Oncol 2016; 7:59-69. [PMID: 28983366 PMCID: PMC5624701 DOI: 10.14740/wjon976w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/10/2016] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Incidence rates of adult low-grade primary brain tumors have previously been widely analyzed nationwide across the world, and most of these studies include data on incidence rates in men and women separately. However, to our knowledge, no worldwide international comparison has been made on possible differences in incidence rates of low-grade brain tumors between men and women. The primary aim was to review the incidence rates between men and women in adult low-grade primary brain tumors. METHODS We searched for published articles in internationally peer reviewed journals that were identified through a systematic search of PubMed. Because of difficulties in interpreting data, we excluded all studies only including patient data before the second edition of World Health Organization (WHO) histological classification system of brain tumors (1993). We also made an overall analysis to calculate incidence rates of low-grade brain tumors in men and women separately. RESULTS A total of 14 studies from the United States and Europe were reviewed. Overall mean age-adjusted incidence rate in men was 1.07 per 100,000 compared to 1.70 per 100,000 in women. No significant difference was seen in age-adjusted incidence rate between genders (Mann-Whitney U test; P = 0.8347). No significant trend of age-adjusted incidence rate was seen in male patients (P = 0.757) nor in women (P = 0.354). CONCLUSION The results must be interpreted with caution and more large international studies are warranted and should be made in a standardized manner differing low-grade tumors from high-grade tumors according to the WHO 2007 brain tumor classification system. Also future studies should always state the ICD-O histology coding to ease future interpretations.
Collapse
Affiliation(s)
- Jonas Nilsson
- Center for Research & Development, Uppsala University/County Council of Gavleborg, Gavle Hospital, SE-801 87 Gavle, Sweden
- Department of Radiation Sciences & Oncology, Umea University Hospital, SE-901 87 Umea, Sweden
- Department of Radiology, Gavle Hospiral, SE-801 87 Gavle, Sweden
| | - Georg Holgersson
- Center for Research & Development, Uppsala University/County Council of Gavleborg, Gavle Hospital, SE-801 87 Gavle, Sweden
- Department of Oncology, Gavle Hospital, SE-801 87 Gavle, Sweden
| | - Tobias Carlsson
- Department of Oncology, Gavle Hospital, SE-801 87 Gavle, Sweden
| | - Roger Henriksson
- Department of Radiation Sciences & Oncology, Umea University Hospital, SE-901 87 Umea, Sweden
- Regional Cancer Center Stockholm, Gotland, Sweden
| | - Stefan Bergstrom
- Center for Research & Development, Uppsala University/County Council of Gavleborg, Gavle Hospital, SE-801 87 Gavle, Sweden
- Department of Oncology, Gavle Hospital, SE-801 87 Gavle, Sweden
| | - Michael Bergqvist
- Center for Research & Development, Uppsala University/County Council of Gavleborg, Gavle Hospital, SE-801 87 Gavle, Sweden
- Department of Radiation Sciences & Oncology, Umea University Hospital, SE-901 87 Umea, Sweden
- Department of Oncology, Gavle Hospital, SE-801 87 Gavle, Sweden
| |
Collapse
|
74
|
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers (Basel) 2016; 8:cancers8080071. [PMID: 27472363 PMCID: PMC4999780 DOI: 10.3390/cancers8080071] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 06/30/2016] [Accepted: 07/19/2016] [Indexed: 01/06/2023] Open
Abstract
Malignant brain tumors continue to represent a devastating diagnosis with no real chance for cure. Despite an increasing list of potential salvage therapies, standard-of-care for these patients has not changed in over a decade. Immunotherapy has been seen as an exciting option, with the potential to offer specific and long lasting tumor clearance. The “gold standard” in immunotherapy has been the development of a tumor-specific CD8 T cell response to potentiate tumor clearance and immunological memory. While many advances have been made in the field of immunotherapy, few therapies have seen true success. Many of the same principles used to develop immunotherapy in tumors of the peripheral organs have been applied to brain tumor immunotherapy. The immune-specialized nature of the brain should call into question whether this approach is appropriate. Recent results from our own experiments require a rethinking of current dogma. Perhaps a CD8 T cell response is not sufficient for an organ as immunologically unique as the brain. Examination of previously elucidated principles of the brain’s immune-specialized status and known immunological preferences should generate discussion and experimentation to address the failure of current therapies.
Collapse
|
75
|
Wegman-Ostrosky T, Reynoso-Noverón N, Mejía-Pérez SI, Sánchez-Correa TE, Alvarez-Gómez RM, Vidal-Millán S, Cacho-Díaz B, Sánchez-Corona J, Herrera-Montalvo LA, Corona-Vázquez T. Clinical prognostic factors in adults with astrocytoma: Historic cohort. Clin Neurol Neurosurg 2016; 146:116-22. [PMID: 27208871 DOI: 10.1016/j.clineuro.2016.05.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Revised: 04/24/2016] [Accepted: 05/03/2016] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To explore the clinical prognostic factors for adults affected with astrocytoma. PATIENTS AND METHODS Using a historic cohort, we selected 155 clinical files from patients with astrocytoma using simple randomization. The main outcome variable was overall survival time. To identify clinical prognostic factors, we used bivariate analysis, Kaplan Meier, the log rank test and the Cox regression models. The number of lost years lived with disability (DALY) based on prevalence, was calculated. RESULTS The mean age at diagnosis was 45.7 years. Analysis according to tumour stage, including grades II, III and IV, also showed a younger age of presentation. Kaplan-Meier survival estimates showed that tumour grade, Karnofsky status (KPS) ≥70, resection type, chemotherapy, radiotherapy, alcohol consumption, familial history of cancer and clinical presentation were significantly associated with survival time. Using a proportional hazard model, age, grade IV, resection, chemotherapy+radiotherapy and KPS were identified as prognostic factors.The amount of life lost due to premature death in this population was 28 years. CONCLUSION In our study, astrocytoma was diagnosed in young adults. The overall survival was 15 months, 9% (n=14) of patients presented a survival of 2 years, and 3% of patients survived 3 years. On average the number of years lost due to premature death and disability was 28.53 years.
Collapse
Affiliation(s)
- Talia Wegman-Ostrosky
- Dirección de Investigación, Instituto Nacional de Cancerologia, San Fernando 22, Sección XVI, CP 14080 Tlalpan, CDMX, Mexico.
| | - Nancy Reynoso-Noverón
- Dirección de Investigación, Instituto Nacional de Cancerologia, San Fernando 22, Sección XVI, CP 14080 Tlalpan, CDMX, Mexico.
| | - Sonia I Mejía-Pérez
- Subdirección de Neurocirugía, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur # 3877, CP 14269 Tlalpan, CDMX, Mexico.
| | - Thalía E Sánchez-Correa
- Subdirección de Neurocirugía, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur # 3877, CP 14269 Tlalpan, CDMX, Mexico.
| | - Rosa María Alvarez-Gómez
- Dirección de Investigación, Instituto Nacional de Cancerologia, San Fernando 22, Sección XVI, CP 14080 Tlalpan, CDMX, Mexico.
| | - Silvia Vidal-Millán
- Dirección de Investigación, Instituto Nacional de Cancerologia, San Fernando 22, Sección XVI, CP 14080 Tlalpan, CDMX, Mexico.
| | - Bernardo Cacho-Díaz
- Departamento Neuro-oncologia, Instituto Nacional de Cancerologia San Fernando 22, Sección XVI, CP 14080 Tlalpan, CDMX, Mexico.
| | - José Sánchez-Corona
- Dirección Centro de Investigaciones Biomedicas, Cetro Médico de Occidente, IMSS, Sierra mojada 800, 44340 Guadalajara, Jalisco, Mexico.
| | - Luis A Herrera-Montalvo
- Dirección de Investigación, Instituto Nacional de Cancerologia, San Fernando 22, Sección XVI, CP 14080 Tlalpan, CDMX, Mexico.
| | - Teresa Corona-Vázquez
- Laboratorio Clínico de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur # 3877, CP 14269 Tlalpan, CDMX, Mexico.
| |
Collapse
|
76
|
Mylam KJ, Michaelsen TY, Hutchings M, Jacobsen Pulczynski E, Pedersen LM, Braendstrup P, Gade IL, Eberlein TR, Gang AO, Bøgsted M, Brown PDN, El-Galaly TC. Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study. Br J Haematol 2016; 176:671-673. [PMID: 26913572 DOI: 10.1111/bjh.13988] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Karen Juul Mylam
- Department of Haematology, Odense University Hospital, Odense, Denmark
| | | | - Martin Hutchings
- Department of Haematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | | | | | - Peter Braendstrup
- Department of Haematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | - Inger Lise Gade
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
| | | | | | - Martin Bøgsted
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
| | - Peter de Nully Brown
- Department of Haematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | - Tarec Christoffer El-Galaly
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
| |
Collapse
|
77
|
Pouchieu C, Baldi I, Gruber A, Berteaud E, Carles C, Loiseau H. Descriptive epidemiology and risk factors of primary central nervous system tumors: Current knowledge. Rev Neurol (Paris) 2015; 172:46-55. [PMID: 26708326 DOI: 10.1016/j.neurol.2015.10.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Revised: 10/08/2015] [Accepted: 10/09/2015] [Indexed: 11/16/2022]
Abstract
Although comparisons are difficult due to differences in methodologies, the annual incidence rates of central nervous system (CNS) tumors range from 8.5 to 21.4/100,000 population according to cancer registries, with a predominance of neuroepithelial tumors in men and meningiomas in women. An increase in the incidence of CNS tumors has been observed during the past decades in several countries. It has been suggested that this trend could be due to aging of the population, and improvements in diagnostic imaging and healthcare access, but these factors do not explain differences in incidence by gender and histological subtypes. Several etiological hypotheses related to intrinsic (sociodemographic, anthropometric, hormonal, immunological, genetic) and exogenous (ionizing radiation, electromagnetic fields, diet, infections, pesticides, drugs) risk factors have led to analytical epidemiological studies to establish relationships with CNS tumors. The only established environmental risk factor for CNS tumors is ionizing radiation exposure. However, for other risk factors, studies have been inconsistent and inconclusive due to systematic differences in study design and difficulties in accurately measuring exposures. Thus, the etiology of CNS tumors is complex and may involve several genetic and/or environmental factors that may act differently according to histological subtype.
Collapse
Affiliation(s)
- C Pouchieu
- ISPED, Équipe Santé Travail Environnement, Université de Bordeaux, 33000 Bordeaux, France; Inserm, ISPED, Centre Inserm U1219, Bordeaux Population Health Center, 33000 Bordeaux, France
| | - I Baldi
- ISPED, Équipe Santé Travail Environnement, Université de Bordeaux, 33000 Bordeaux, France; Inserm, ISPED, Centre Inserm U1219, Bordeaux Population Health Center, 33000 Bordeaux, France; Service de médecine du travail, CHU de Bordeaux, 33000 Bordeaux, France.
| | - A Gruber
- ISPED, Équipe Santé Travail Environnement, Université de Bordeaux, 33000 Bordeaux, France; Inserm, ISPED, Centre Inserm U1219, Bordeaux Population Health Center, 33000 Bordeaux, France
| | - E Berteaud
- ISPED, Équipe Santé Travail Environnement, Université de Bordeaux, 33000 Bordeaux, France; Inserm, ISPED, Centre Inserm U1219, Bordeaux Population Health Center, 33000 Bordeaux, France; Service de médecine du travail, CHU de Bordeaux, 33000 Bordeaux, France
| | - C Carles
- ISPED, Équipe Santé Travail Environnement, Université de Bordeaux, 33000 Bordeaux, France; Inserm, ISPED, Centre Inserm U1219, Bordeaux Population Health Center, 33000 Bordeaux, France; Service de médecine du travail, CHU de Bordeaux, 33000 Bordeaux, France
| | - H Loiseau
- Service de neurochirurgie, CHU de Bordeaux, 33000 Bordeaux, France
| |
Collapse
|
78
|
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 Suppl 4:iv1-iv62. [PMID: 26511214 DOI: 10.1093/neuonc/nov189] [Citation(s) in RCA: 1491] [Impact Index Per Article: 165.7] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Affiliation(s)
- Quinn T Ostrom
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA Central Brain Tumor Registry of the United States, Hinsdale, IL USA
| | - Haley Gittleman
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA Central Brain Tumor Registry of the United States, Hinsdale, IL USA
| | - Jordonna Fulop
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA
| | - Max Liu
- Solon High School, Solon, OH USA
| | | | - Courtney Kromer
- Case Western Reserve University School of Medicine, Cleveland, OH USA
| | - Yingli Wolinsky
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA Central Brain Tumor Registry of the United States, Hinsdale, IL USA
| | - Carol Kruchko
- Central Brain Tumor Registry of the United States, Hinsdale, IL USA
| | - Jill S Barnholtz-Sloan
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA Central Brain Tumor Registry of the United States, Hinsdale, IL USA
| |
Collapse
|
79
|
Rouse C, Gittleman H, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro Oncol 2015; 18:70-7. [PMID: 26459813 DOI: 10.1093/neuonc/nov249] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 09/06/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Years of potential life lost (YPLL) complement incidence and survival rates by measuring how much a patient's life is likely to be shortened by his or her cancer. In this study, we examine the impact of death due to brain and other central nervous system (CNS) tumors compared to other common cancers in adults by investigating the YPLL of adults in the United States. METHODS Mortality and life table data were obtained from the Centers for Disease Control and Prevention's National Center for Health Statistics Vital Statistics Data for 2010. The study population included individuals aged 20 years or older at death who died from one of the selected cancers. YPLL was calculated by taking an individual's age at death and finding the corresponding expected remaining years of life using life table data. RESULTS The cancers with the greatest mean YPLL were other malignant CNS tumors (20.65), malignant brain tumors (19.93), and pancreatic cancer (15.13) for males and malignant brain tumors (20.31), breast cancer (18.78), and other malignant CNS tumors (18.36) for females. For both sexes, non-Hispanic whites had the lowest YPLL, followed by non-Hispanic blacks, and Hispanics. CONCLUSION Malignant brain and other CNS tumors have the greatest mean YPLL, thereby reflecting their short survival time post diagnosis. These findings will hopefully motivate more research into mitigating the impact of these debilitating tumors.
Collapse
Affiliation(s)
- Chaturia Rouse
- Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio (C.R.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (H.G., Q.T.O., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (H.G., Q.T.O., C. K., J.S.B.-S.)
| | - Haley Gittleman
- Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio (C.R.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (H.G., Q.T.O., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (H.G., Q.T.O., C. K., J.S.B.-S.)
| | - Quinn T Ostrom
- Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio (C.R.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (H.G., Q.T.O., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (H.G., Q.T.O., C. K., J.S.B.-S.)
| | - Carol Kruchko
- Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio (C.R.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (H.G., Q.T.O., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (H.G., Q.T.O., C. K., J.S.B.-S.)
| | - Jill S Barnholtz-Sloan
- Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio (C.R.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (H.G., Q.T.O., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (H.G., Q.T.O., C. K., J.S.B.-S.)
| |
Collapse
|
80
|
Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Demetriou A, Cozma R, Coza D, Bouka E, Dessypris N, Kantzanou M, Kanavidis P, Dana H, Hatzipantelis E, Moschovi M, Polychronopoulou S, Pourtsidis A, Stiakaki E, Papakonstantinou E, Oikonomou K, Sgouros S, Vakis A, Zountsas B, Bourgioti C, Kelekis N, Prassopoulos P, Choreftaki T, Papadopoulos S, Stefanaki K, Strantzia K, Cardis E, Steliarova-Foucher E, Petridou ET. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries. Eur J Cancer 2015; 51:1444-55. [PMID: 25971531 DOI: 10.1016/j.ejca.2015.04.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Revised: 04/17/2015] [Accepted: 04/21/2015] [Indexed: 12/28/2022]
Abstract
AIM Following completion of the first 5-year nationwide childhood (0-14 years) registration in Greece, central nervous system (CNS) tumour incidence rates are compared with those of 12 registries operating in 10 Southern-Eastern European countries. METHODS All CNS tumours, as defined by the International Classification of Childhood Cancer (ICCC-3) and registered in any period between 1983 and 2014 were collected from the collaborating cancer registries. Data were evaluated using standard International Agency for Research on Cancer (IARC) criteria. Crude and age-adjusted incidence rates (AIR) by age/gender/diagnostic subgroup were calculated, whereas time trends were assessed through Poisson and Joinpoint regression models. RESULTS 6062 CNS tumours were retrieved with non-malignant CNS tumours recorded in eight registries; therefore, the analyses were performed on 5191 malignant tumours. Proportion of death certificate only cases was low and morphologic verification overall high; yet five registries presented >10% unspecified neoplasms. The male/female ratio was 1.3 and incidence decreased gradually with age, apart from Turkey and Ukraine. Overall AIR for malignant tumours was 23/10(6) children, with the highest rates noted in Croatia and Serbia. A statistically significant AIR increase was noted in Bulgaria, whereas significant decreases were noted in Belarus, Croatia, Cyprus and Serbia. Although astrocytomas were overall the most common subgroup (30%) followed by embryonal tumours (26%), the latter was the predominant subgroup in six registries. CONCLUSION Childhood cancer registration is expanding in Southern-Eastern Europe. The heterogeneity in registration practices and incidence patterns of CNS tumours necessitates further investigation aiming to provide clues in aetiology and direct investments into surveillance and early tumour detection.
Collapse
Affiliation(s)
- Paraskevi Papathoma
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Thomas P Thomopoulos
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Maria A Karalexi
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Anton Ryzhov
- National Cancer Registry of Ukraine, National Institute of Cancer, Kyiv, Ukraine
| | - Anna Zborovskaya
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology , Childhood Cancer Subregistry of Belarus, Minsk, Belarus
| | - Nadya Dimitrova
- Bulgarian National Cancer Registry, National Oncology Hospital, Sofia, Bulgaria
| | | | - Sultan Eser
- Izmir Cancer Registry, Izmir Hub, Izmir & Hacettepe University Institute of Public Health, Ankara, Turkey
| | - Luís Antunes
- North Region Cancer Registry of Portugal (RORENO), Portuguese Oncology Institute of Porto, Portugal
| | - Mario Sekerija
- Croatian National Cancer Registry, Croatian Institute of Public Health, Zagreb, Croatia
| | - Tina Zagar
- Cancer Registry of Republic of Slovenia, Institute of Oncology, Ljubljana, Slovenia
| | - Joana Bastos
- Registo Oncológico Regional do Centro, Instituto Português de Oncologia de Coimbra, Francisco Gentil E.P.E, Coimbra, Portugal
| | - Anna Demetriou
- Cyprus Cancer Registry-Health Monitoring Unit, Ministry of Health, Nicosia, Cyprus
| | - Raluca Cozma
- Northeast Regional Cancer Registry, Regional Center of Public Health, 14 Victor Babes Street, 700465 Iasi, Romania
| | - Daniela Coza
- Regional Cancer Registry of Cluj, Oncological Institute "Ion Chiricuta", Cluj-Napoca, Romania
| | - Evdoxia Bouka
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Nick Dessypris
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Maria Kantzanou
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Prodromos Kanavidis
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece
| | - Helen Dana
- Oncology Department, "Mitera" Childrens Hospital, ErythrouStavrou 6 Marousi, Athens, Greece
| | - Emmanuel Hatzipantelis
- 2nd Department of Pediatrics, Aristotelion University of Thessaloniki, AHEPA General Hospital, Thessaloniki, Greece
| | - Maria Moschovi
- Haematology-Oncology Unit, First Department of Pediatrics, Athens University Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece
| | - Sophia Polychronopoulou
- Department of Pediatric Haematology-Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece
| | - Apostolos Pourtsidis
- Department of Pediatric Hematology-Oncology, "Pan. & Agl. Kyriakou" Children's Hospital, Athens, Greece
| | - Eftichia Stiakaki
- Department of Pediatric Hematology-Oncology, University of Crete, University Hospital of Heraklion, Heraklion, Greece
| | | | | | - Spyros Sgouros
- Department of Neurosurgery, "Mitera" Childrens Hospital, Erythrou Stavrou 6 Marousi, Athens, Greece
| | - Antonios Vakis
- Department of Neurosurgery, University Hospital of Heraklion, Heraklion, Crete, Greece
| | - Basilios Zountsas
- Department of Neurosurgery, St. Luke's Hospital, Panorama, Thessaloniki, Greece
| | - Charis Bourgioti
- First Department of Radiology, Aretaieion Hospital, Medical School, University of Athens, Athens, Greece
| | - Nikolaos Kelekis
- 2nd Department of Radiology, Radiotherapy Unit, Medical School, National Kapodistrian University of Athens, Athens, Greece
| | - Panos Prassopoulos
- Department of Radiology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - Theodosia Choreftaki
- Department of Pathology, "G. Gennimatas" Athens General Hospital, Athens, Greece
| | | | - Kalliopi Stefanaki
- Histopathology Department, "Aghia Sophia" Children's Hospital, Athens, Greece
| | - Katerina Strantzia
- Histopathology Department, "Pan. & Agl. Kyriakou" Children's Hospital, Athens, Greece
| | - Elisabeth Cardis
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - Eva Steliarova-Foucher
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - Eleni Th Petridou
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Greece.
| |
Collapse
|
81
|
Ugarte MD, Adin A, Goicoa T, López-Abente G. Analyzing the evolution of young people's brain cancer mortality in Spanish provinces. Cancer Epidemiol 2015; 39:480-5. [PMID: 25907644 DOI: 10.1016/j.canep.2015.03.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Revised: 03/03/2015] [Accepted: 03/31/2015] [Indexed: 01/19/2023]
Abstract
OBJECTIVES To analyze the spatio-temporal evolution of brain cancer relative mortality risks in young population (under 20 years of age) in Spanish provinces during the period 1986-2010. METHODS A new and flexible conditional autoregressive spatio-temporal model with two levels of spatial aggregation was used. RESULTS Brain cancer relative mortality risks in young population in Spanish provinces decreased during the last years, although a clear increase was observed during the 1990s. The global geographical pattern emphasized a high relative mortality risk in Navarre and a low relative mortality risk in Madrid. Although there is a specific Autonomous Region-time interaction effect on the relative mortality risks this effect is weak in the final estimates when compared to the global spatial and temporal effects. CONCLUSIONS Differences in mortality between regions and over time may be caused by the increase in survival rates, the differences in treatment or the availability of diagnostic tools. The increase in relative risks observed in the 1990s was probably due to improved diagnostics with computerized axial tomography and magnetic resonance imaging techniques.
Collapse
Affiliation(s)
- M D Ugarte
- Department of Statistics and O.R., Public University of Navarre, Spain; Institute for Advanced Materials (INAMAT), Public University of Navarre, Spain.
| | - A Adin
- Department of Statistics and O.R., Public University of Navarre, Spain
| | - T Goicoa
- Department of Statistics and O.R., Public University of Navarre, Spain; Institute for Advanced Materials (INAMAT), Public University of Navarre, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Spain
| | - G López-Abente
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain
| |
Collapse
|
82
|
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. Response to "the epidemiology of glioma in adults: a 'state of the science' review". Neuro Oncol 2015; 17:624-6. [PMID: 25762697 PMCID: PMC4483084 DOI: 10.1093/neuonc/nov022] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Affiliation(s)
- Quinn T Ostrom
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Luc Bauchet
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Faith G Davis
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Isabelle Deltour
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - James L Fisher
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Chelsea Eastman Langer
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Melike Pekmezci
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Judith A Schwartzbaum
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Michelle C Turner
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Kyle M Walsh
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Margaret R Wrensch
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| | - Jill S Barnholtz-Sloan
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., J.B.S.); Centre Hospitalo-Universitaire Montpellier and Institut National de la Sante et de la Recherche Medicale, Montpellier, France (L.B.); School of Public Heath, University of Alberta, Edmonton, Canada (F.G.D); International Agency for Research on Cancer, Lyon, France (I.D.); The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio (J.L.F.); Centre for Research in Environmental Epidemiology, Barcelona, Spain (C.E.L, M.C.T.); Universitat Pompeu Fabra, Barcelona, Spain (C.E.L., M.C.T.); C.I.B.E.R Epidemiología y Salud Pública, Barcelona, Spain (C.E.L., M.C.T.); Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California (M.P.); Department of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio (J.A.S); McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada (M.C.T); Department of Neurological Surgery, University of California, San Francisco School of Medicine, San Francisco, California (K.M.W., M.R.W.)
| |
Collapse
|